Surface Oncology Inc SURF:NASDAQ

Last Price$1.74NASDAQ Previous Close - Last Trade as of 4:00PM ET 6/28/22

Today's Change-0.08(4.40%)
Bid (Size)$1.58 (3)
Ask (Size)$2.09 (3)
Day Low / High$1.72 - 1.85
Volume321.4 K

Surface Oncology Starts Two Mid-Stage Trials of Experimental Cancer Drug

8:13AM ET 4/14/2022 MT Newswires
Surface Oncology (SURF) said Thursday it has started two mid-stage trials on its experimental cancer drug SRF388 as a standalone therapy and as a part of a combination treatment.

The first phase 2 study will enroll about 100 liver cancer patients who had no prior treatment, the company said. It will test the ability of SRF388 in improving progression-free survival when combined with Roche's atezolizumab and bevacizumab. Final data are expected in the first half of 2024.

The second phase 2 trial is enrolling up to 40 non-small-cell lung cancer patients who had at least one round of treatment to test SRF388 as a standalone therapy. The primary endpoint will be overall response rate, with data readout expected next year.

The drugmaker's shares were up 4.6% in recent early premarket activity Thursday.

Price: 2.75, Change: +0.12, Percent Change: +4.56